Lampalizumab

Summary

Lampalizumab is an intravitreally administered antigen‑binding fragment (Fab) that targets complement factor D, a key enzyme in the alternative complement pathway. It has been investigated in phase 2 and phase 3 clinical trials for geographic atrophy (GA), the advanced dry form of age‑related macular degeneration (AMD). The drug remains investigational and has not demonstrated clinically meaningful slowing of GA progression or visual‑function improvement.

Mechanism of Action

Lampalizumab binds specifically to complement factor D, the rate‑limiting serine protease that cleaves factor B in the alternative complement cascade. By inhibiting factor D, the drug prevents formation of the C3 convertase (C3bBb), reducing downstream complement activation, opsonisation, and inflammatory damage in the retinal pigment epithelium that contributes to GA development.

What the Research Shows

Early phase 2 data suggested lampalizumab could slow GA enlargement, prompting large phase 3 trials (Chroma and Spectri). Both trials, enrolling over 1800 participants, found no statistically or clinically significant reduction in GA lesion growth compared with sham at 48 weeks, regardless of dosing interval or genetic sub‑group. A 2023 Cochrane review synthesized these results and confirmed the lack of efficacy across visual‑acuity and anatomical endpoints, while noting a modest anatomical benefit for other complement inhibitors. Post‑hoc analyses of intra‑ocular pressure showed no sustained IOP rise, and endophthalmitis occurred in 0.04% of injections. Overall, evidence indicates lampalizumab does not improve functional outcomes in GA.

Reported Benefits

Evidence from the trials does not support a benefit of lampalizumab in slowing GA lesion expansion or preserving visual acuity. The drug’s safety profile shows a low rate of injection‑related complications, such as endophthalmitis (≈0.04%) and minimal intra‑ocular pressure changes, suggesting it is well tolerated when administered intravitreally.

Limitations of the Evidence

Phase 3 trials demonstrated no meaningful anatomical or functional benefit, and subgroup analyses (including complement factor I genotype) failed to reveal responsive populations. The evidence base is limited to GA secondary to AMD; no data exist for other ocular conditions. Potential increased risk of macular neovascularisation was suggested but remains low‑certainty. Long‑term safety beyond one year is not established.

Safety Considerations

Adverse events were comparable to intravitreal anti‑VEGF agents. Endophthalmitis occurred in 5 of 12,447 injections (0.04%). Intra‑ocular pressure elevations were rare and not more frequent than in sham groups. Low‑certainty data hint at a possible rise in macular neovascularisation, but overall the drug was well tolerated in trial settings.

How It Is Administered

Lampalizumab is delivered by intravitreal injection, typically 10 mg in a 0.1 mL volume. Clinical studies used dosing intervals of every 4 weeks or every 6 weeks over a 48‑week period. The formulation is a sterile aqueous solution for ocular use.

Routes of Administration

Goals & Uses

• Geographic atrophy (AMD)OphthalmologyModerate
• Visual acuity preservation in geographic atrophyFunctional OutcomesLow
• Reduction of geographic atrophy lesion growthOphthalmology / Retinal DiseaseLow
• Complement pathway inhibition in AMDMechanistic / PharmacologicalModerate

Contraindications

• Active intraocular inflammationInflammatoryModerate
• Severe intraocular inflammationOcularModerate
• Hypersensitivity to lampalizumab or any excipientImmunologicHigh
• Ocular or periocular infectionInfectiousHigh
• Active ocular infectionOphthalmologyHigh

Adverse Effects

• Increased intraocular pressureOcularRare
• Retinal detachmentOcularRare
• Conjunctival hemorrhageOcularCommon
• Intraocular inflammationOcularUncommon
• Vitreous floatersOcularCommon
• EndophthalmitisOcular / InfectiousRare
• Susceptibility to encapsulated bacterial infectionsImmunologic / InfectiousUnknown

Drug Interactions

• Other intravitreal agents (e.g., anti‑VEGF)Moderate
• Other complement inhibitorsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeAbsolute
• Patients with systemic complement deficienciesImmunologicRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionInvestigationalDevelopment halted; no EMA approval.
• United StatesInvestigationalPhase III trial failed; no FDA approval.
• United KingdomInvestigationalNo approval; program discontinued globally in 2018.

Phase III trials failed to meet primary endpoints; development discontinued. No regulatory approval in any jurisdiction.

Evidence & Sources

• Complement Inhibitors for Geographic Atrophy in Age-Related Macular Degeneration-A Systematic Review
  Journal ArticleModerateDascalu AM, et al.2024-01-01T00:00:00.000000Z
• Complement inhibitors for age-related macular degeneration
  Journal ArticleModerateTzoumas N, et al.2023-01-01T00:00:00.000000Z
• Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy
  Journal ArticleModerateJack LS, et al.2016-01-01T00:00:00.000000Z
• Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy
  Journal ArticleModerateBressler NM, et al.2024-01-01T00:00:00.000000Z
• Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials
  Journal ArticleModerateHolz FG, et al.2018-01-01T00:00:00.000000Z
• Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials
  Journal ArticleModerateAnegondi N, et al.2025-01-01T00:00:00.000000Z

Frequently Asked Questions